Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/32365
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBallester, Purificación-
dc.contributor.authorMuriel, Javier-
dc.contributor.authorPeiró, Ana-
dc.contributor.otherDepartamentos de la UMH::Farmacología, Pediatría y Química Orgánicaes_ES
dc.date.accessioned2024-06-27T11:38:07Z-
dc.date.available2024-06-27T11:38:07Z-
dc.date.created2022-04-
dc.identifier.citationExpert Opinion Drug Metabolism&Toxicology . 2022 Apr;18(4):261-275es_ES
dc.identifier.issn1744-7607-
dc.identifier.urihttps://hdl.handle.net/11000/32365-
dc.description.abstractIntroduction: Opioids play a fundamental role in chronic pain, especially considering when 1 of 5 Europeans adults, even more in older females, suffer from it. However, half of them do not reach an adequate pain relief. Could pharmacogenomics help to choose the most appropriate analgesic drug?. Areas covered: The objective of the present narrative review was to assess the influence of cytochrome P450 2D6 (CYP2D6) phenotypes on pain relief, analgesic tolerability, and potential opioid misuse. Until December 2021, a literature search was conducted through the MEDLINE, PubMed database, including papers from the last 10 years. CYP2D6 plays a major role in metabolism that directly impacts on opioid (tramadol, codeine, or oxycodone) concentration with differences between sexes, with a female trend toward poorer pain control. In fact, CYP2D6 gene variants are the most actionable to be translated into clinical practice according to regulatory drug agencies and international guidelines. Expert opinion: CYP2D6 genotype can influence opioids' pharmacokinetics, effectiveness, side effects, and average opioid dose. This knowledge needs to be incorporated in pain management. Environmental factors, psychological together with genetic factors, under a sex perspective, must be considered when you are selecting the most personalized pain therapy for your patients.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent38es_ES
dc.language.isoenges_ES
dc.publisherTaylor&Francises_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectchronic paines_ES
dc.subjectpersonalized analgesiaes_ES
dc.subjectCYP2D6 phenotypeses_ES
dc.subjectopioid metabolismes_ES
dc.subjectpharmacogeneticses_ES
dc.subjectsexes_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::615 - Farmacología. Terapéutica. Toxicología. Radiologíaes_ES
dc.titleCYP2D6 phenotypes and opioid metabolism: the path to personalized analgesiaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1080/17425255.2022.2085552es_ES
Appears in Collections:
Artículos Farmacología, Pediatría y Química Orgánica


no-thumbnailView/Open:

 CYP2D6 phenotypes and opioid metabolism. the path to personalised analgesia.pdf



2,55 MB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???